Cirtuvivint plus olaparib for BRCA/HRD ovarian cancer that stopped responding to platinum
Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer
This work adds cirtuvivint to the PARP drug olaparib to try to help people with BRCA-mutated or homologous recombination–deficient ovarian cancer that no longer responds to platinum chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11179129 on NIH RePORTER |
What this research studies
Researchers are exploring whether the new drug cirtuvivint can make the PARP inhibitor olaparib work again for people whose BRCA- or HRD-driven ovarian cancer has become resistant to platinum and PARP therapy. In the lab they will study how the drugs act together on cancer cells and animal models, focusing on changes in RNA splicing, Wnt signaling, and DNA R-loop formation that may make tumors more vulnerable. The team will also use tumor samples and preclinical models to measure whether the combination reverses resistance. If the preclinical results are promising, the work could support future clinical trials offering the combination to patients.
Who could benefit from this research
Good fit: People with ovarian cancer whose tumors have BRCA1/2 mutations or homologous recombination deficiency and whose disease recurred after platinum chemotherapy and became resistant to PARP inhibitors are the most likely candidates.
Not a fit: Patients whose tumors do not have BRCA mutations or HRD, whose disease remains platinum- and PARP-sensitive, or who cannot tolerate these drugs are less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could restore response to PARP inhibitors and offer a new treatment option for patients with platinum- and PARP-resistant BRCA/HRD ovarian cancer.
How similar studies have performed: Other combinations aimed at overcoming PARP resistance have shown promise in preclinical and early clinical work, but using cirtuvivint, a first-in-class CLK/DYRK inhibitor, with olaparib is a new, mainly preclinical strategy.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Corr, Bradley — University of Colorado Denver
- Study coordinator: Corr, Bradley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.